Noel Tata reportedly told shareholders at Trent's annual general meeting that it would be his last as chairman, signalling the close of a t...

Palestine's Embassy in India has issued a dire plea for immediate medical aid, warning of a healthcare sector collapse due to ongoing confl...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

NephroPlus, India's leading provider of dialysis services, is on a mission to reshape the future of kidney health with an innovative tech-b...

Geopolitical shifts and the drive for self-reliance are creating long-term investment opportunities in India's defence and electrification ...

Manipur Chief Minister Yumnam Khemchand Singh urged NITI Aayog to spearhead the state's economic recovery and long-term development, emphas...

Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...

West Bengal is exploring ways to expand electronics manufacturing under EMC 2.0. This and more in today's ETtech Top 5.

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

Israel and Lebanon have agreed to a ceasefire brokered by the United States. This development offers hope for de-escalation in the ongoing ...

Major private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition high...

Ajay Bagga offers a clear strategy for Indian markets. He advises waiting for real AI revenue in IT. Pharma remains a strong investment due...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achievi...

Max Healthcare Q4FY26 consolidated PAT grew 7% YoY, and revenue increased 12%. Network EBITDA rose 8%. Max Lab and Max@Home saw strong doub...